Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions

키워드

참고문헌 (349)

1. Czaja AJ, "Diverse manifestations and evolving treatments of autoimmune hepatitis", Minerva Gastroenterol Dietol, 51, pp.313~333 (2005)
2. Czaja AJ, "Special clinical challenges in autoimmune hepatitis:the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients", Semin Liver Dis, 29, pp.315~330 (2009)
3. Czaja AJ, "Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment", World J Gastroenterol, 15, pp.2314~2328 (2009)
4. Czaja AJ, "Autoimmune hepatitis in special patient populations", Best Pract Res Clin Gastroenterol, 25, pp.689~700 (2011)
5. Czaja AJ, "Autoimmune hepatitis in diverse ethnic populations and geographical regions", Expert Rev Gastroenterol Hepatol, 7, pp.365~385 (2013)
6. Cowling DC, "Lupoid hepatitis", Lancet, 271, pp.1323~1326 (1956)
7. Read AE, "Active ‘juvenile’ cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy", Gut, 4, pp.378~393 (1963)
8. Mackay IR, "Auto-immune (lupoid) hepatitis: an entity in the spectrum of chronic active liver disease", J Gastroenterol Hepatol, 5, pp.352~359 (1990)
9. Czaja AJ, "Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis", Am J Gastroenterol, 97, pp.2051~2057 (2002)
10. Al-Chalabi T, "Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis", J Hepatol, 48, pp.140~147 (2008)
11. Gregorio GV, "Autoimmune hepatitis in childhood: a 20-year experience", Hepatology, 25, pp.541~547 (1997)
12. Czaja AJ, "Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States", J Hepatol, 37, pp.302~308 (2002)
13. Al-Chalabi T, "Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre", J Hepatol, 45, pp.575~583 (2006)
14. Czaja AJ, "Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly", Hepatology, 43, pp.532~538 (2006)
15. Zolfino T, "Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin", Gut, 50, pp.713~717 (2002)
16. Czaja AJ, "Autoimmune hepatitis. Part B: diagnosis", Expert Rev Gastroenterol Hepatol, 1, pp.129~143 (2007)
17. Manns MP, "Diagnosis and management of autoimmune hepatitis", Hepatology, 51, pp.2193~2213 (2010)
18. Czaja AJ, "Diagnosis and management of autoimmune hepatitis", Clin Liver Dis, 19, pp.57~79 (2015)
19. Alvarez F, "International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis", J Hepatol, 31, pp.929~938 (1999)
20. Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
21. Czaja AJ, "Performance parameters of the diagnostic scoring systems for autoimmune hepatitis", Hepatology, 48, pp.1540~1548 (2008)
22. Manns M, "Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen", Lancet, 1, pp.292~294 (1987)
23. Costa M, "Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis", Clin Exp Immunol, 121, pp.364~374 (2000)
24. Czaja AJ, "Antibodies to soluble liver antigen", liver pancreas and HLA risk factors for type 1 autoimmune hepatitis, 2002, pp.97, 413~419
25. Ma Y, "Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease", Hepatology, 35, pp.658~664 (2002)
26. Baeres M, "Establishment of standardised SLA", LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics, 2002, pp.51, 259~264
27. Guéguen P, "Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1", J Clin Immunol, 26, pp.495~505 (2006)
28. Czaja AJ, "Autoantibodies as prognostic markers in autoimmune liver disease", Dig Dis Sci, 55, pp.2144~2161 (2010)
29. Oikonomou KG, "Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity", Autoimmun Rev, 10, pp.389~396 (2011)
30. Zachou K, "Anti-alpha actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1", Aliment Pharmacol Ther, 35, pp.116~125 (2012)
31. Montano-Loza AJ, "Prognostic implications of antibodies to Ro", SSA and soluble liver antigen in type 1 autoimmune hepatitis, 2012, pp.32, 85~92
32. Johnson PJ, "Azathioprine for longterm maintenance of remission in autoimmune hepatitis", N Engl J Med, 333, pp.958~963 (1995)
33. Gleeson D, "British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis", Gut, 60, pp.1611~1629 (2011)
34. Czaja AJ, "Current and prospective pharmacotherapy for autoimmune hepatitis", Expert Opin Pharmacother, 15, pp.1715~1736 (2014)
35. Van Thiel DH, "Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial", Am J Gastroenterol, 90, pp.771~776 (1995)
36. Malekzadeh R, "Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis", Dig Dis Sci, 46, pp.1321~1327 (2001)
37. Devlin SM, "Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy", Can J Gastroenterol, 18, pp.321~326 (2004)
38. Aqel BA, "Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis", J Clin Gastroenterol, 38, pp.805~809 (2004)
39. Czaja AJ, "Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease", J Clin Gastroenterol, 39, pp.819~825 (2005)
40. Inductivo-Yu I, "Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy", Clin Gastroenterol Hepatol, 5, pp.799~802 (2007)
41. Hennes EM, "Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Mycophenolate mofetil in autoimmune hepatitis", Am J Gastroenterol, 103, pp.3063~3070 (2008)
42. Hlivko JT, "A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis", Clin Gastroenterol Hepatol, 6, pp.1036~1040 (2008)
43. Wolf DC, "Mycophenolate mofetil for autoimmune hepatitis: a single practice experience", Dig Dis Sci, 54, pp.2519~2522 (2009)
44. Manns MP, "Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis", Gastroenterology, 139, pp.1198~1206 (2010)
45. Sharzehi K, "Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy", Can J Gastroenterol, 24, pp.588~592 (2010)
46. Baven-Pronk AM, "The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes", Aliment Pharmacol Ther, 34, pp.335~343 (2011)
47. Zachou K, "Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients", J Hepatol, 55, pp.636~646 (2011)
48. Czaja AJ, "Drug choices in autoimmune hepatitis. Part A: steroids", Expert Rev Gastroenterol Hepatol, 6, pp.603~615 (2012)
49. Czaja AJ, "Drug choices in autoimmune hepatitis. Part B: nonsteroids", Expert Rev Gastroenterol Hepatol, 6, pp.617~635 (2012)
50. Czaja AJ, "Autoimmune hepatitis: focusing on treatments other than steroids", Can J Gastroenterol, 26, pp.615~620 (2012)
51. Nasseri-Moghaddam S, "Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial", Middle East J Dig Dis, 5, pp.193~200 (2013)
52. Czaja AJ, "Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis", Dig Dis Sci, 55, pp.2712~2726 (2010)
53. Czaja AJ, "Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis", Curr Pharm Des, 17, pp.3120~3140 (2011)
54. Czaja AJ, "Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part I", Inflamm Allergy Drug Targets, 11, pp.337~350 (2012)
55. Weiler-Normann C, "Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis", J Hepatol, 58, pp.529~534 (2013)
56. Lapierre P, "Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance", Hepatology, 57, pp.217~227 (2013)
57. Czaja AJ, "Targeting apoptosis in autoimmune hepatitis", Dig Dis Sci, 59, pp.2890~2904 (2014)
58. Czaja AJ, "Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets", Aliment Pharmacol Ther, 40, pp.261~279 (2014)
59. Montano-Loza AJ, "Cell mediators of autoimmune hepatitis and their therapeutic implications", Dig Dis Sci, 60, pp.1528~1542 (2015)
60. Czaja AJ, "Adoptive cell transfer in autoimmune hepatitis", Expert Rev Gastroenterol Hepatol, 9, pp.821~836 (2015)
61. Czaja AJ, "Acute and acute severe (fulminant) autoimmune hepatitis", Dig Dis Sci, 58, pp.897~914 (2013)
62. Crapper RM, "‘Acute’ autoimmune hepatitis", Digestion, 34, pp.216~225 (1986)
63. Nikias GA, "The nature and prognostic implications of autoimmune hepatitis with an acute presentation", J Hepatol, 21, pp.866~871 (1994)
64. Michalska Z, "Autoimmune hepatitis in the material of Department and Regional Hospital of Infectious Diseases in Gdańsk", Med Sci Monit, 9(3), pp.49~54 (2003)
65. Ferrari R, "Type 1 autoimmune hepatitis:patterns of clinical presentation and differential diagnosis of the ‘acute’ type", QJM, 97, pp.407~412 (2004)
66. Lee WS, "Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom", J Pediatr Gastroenterol Nutr, 40, pp.575~581 (2005)
67. Stravitz RT, "Autoimmune acute liver failure: proposed clinical and histological criteria", Hepatology, 53, pp.517~526 (2011)
68. Yasui S, "Clinicopathological features of severe and fulminant forms of autoimmune hepatitis", J Gastroenterol, 46, pp.378~390 (2011)
69. Fujiwara K, "Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis", J Gastroenterol, 43, pp.951~958 (2008)
70. Czaja AJ, "Reply: acute and acute severe (fulminant) autoimmune hepatitis", Dig Dis Sci, 58, pp.1809~1810 (2013)
71. Yasui S, "Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure", Hepatol Res, 42, pp.42~50 (2012)
72. Feld JJ, "Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome", Hepatology, 42, pp.53~62 (2005)
73. Kogan J, "Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients", J Clin Gastroenterol, 35, pp.75~81 (2002)
74. Czaja AJ, "Features and consequences of untreated type 1 autoimmune hepatitis", Liver Int, 29, pp.816~823 (2009)
75. Czaja AJ, "Autoantibody-negative autoimmune hepatitis", Dig Dis Sci, 57, pp.610~624 (2012)
76. Czaja AJ, "Cryptogenic chronic hepatitis and its changing guise in adults", Dig Dis Sci, 56, pp.3421~3438 (2011)
77. Czaja AJ, "The nature and prognosis of severe cryptogenic chronic active hepatitis", Gastroenterology, 104, pp.1755~1761 (1993)
78. Heringlake S, "Presumed cryptogenic liver disease in Germany:high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology", Z Gastroenterol, 47, pp.417~423 (2009)
79. Mehendiratta V, "Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 7, pp.98~103 (2009)
80. Seo S, "Favorable outcomes of autoimmune hepatitis in a community clinic setting", J Gastroenterol Hepatol, 23, pp.1410~1414 (2008)
81. Gassert DJ, "Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis", Dig Dis Sci, 52, pp.2433~2437 (2007)
82. Miyake Y, "Current status of autoimmune hepatitis in Japan", Acta Med Okayama, 62, pp.217~226 (2008)
83. Bernal W, "The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study", J Hepatol, 47, pp.664~670 (2007)
84. Hiramatsu A, "Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center", J Gastroenterol Hepatol, 23(8 Pt 1), pp.1216~1222 (2008)
85. McFarlane IG, "Pathogenesis of autoimmune hepatitis", Biomed Pharmacother, 53, pp.255~263 (1999)
86. Czaja AJ, "Behavior and significance of autoantibodies in type 1autoimmune hepatitis", J Hepatol, 30, pp.394~401 (1999)
87. Kanzler S, "Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis", J Hepatol, 31, pp.635~640 (1999)
88. Targan SR, "High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis", Gastroenterology, 108, pp.1159~1166 (1995)
89. Kaukinen K, "Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure", Gastroenterology, 122, pp.881~888 (2002)
90. Abdo A, "Liver abnormalities in celiac disease", Clin Gastroenterol Hepatol, 2, pp.107~112 (2004)
91. Rubio-Tapia A, "Liver involvement in celiac disease", Minerva Med, 99, pp.595~604 (2008)
92. Volta U, "Pathogenesis and clinical significance of liver injury in celiac disease", Clin Rev Allergy Immunol, 36, pp.62~70 (2009)
93. Prasad KK, "Hepatobiliary disorders in celiac disease: an update", Int J Hepatol, 2011, pp.438184~ (2011)
94. Miyake Y, "Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis", Hepatol Res, 37, pp.801~805 (2007)
95. Okano N, "Clinicopathological features of acute-onset autoimmune hepatitis", Hepatol Res, 25, pp.263~270 (2003)
96. Kessler WR, "Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis", Clin Gastroenterol Hepatol, 2, pp.625~631 (2004)
97. Singh R, "Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature", Am J Gastroenterol, 97, pp.2670~2673 (2002)
98. Ludwig J, "Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology", Liver, 4, pp.105~116 (1984)
99. Czaja AJ, "Autoimmune cholangitis within the spectrum of autoimmune liver disease", Hepatology, 31, pp.1231~1238 (2000)
100. Czaja AJ, "Autoimmune hepatitis with incidental histologic features of bile duct injury", Hepatology, 34(4 Pt 1), pp.659~665 (2001)
101. Czaja AJ, "Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis", Liver Int, 24, pp.322~329 (2004)
102. Czaja AJ, "Cholestatic phenotypes of autoimmune hepatitis", Clin Gastroenterol Hepatol, 12, pp.1430~1438 (2014)
103. Kim WR, "Variant forms of cholestatic diseases involving small bile ducts in adults", Am J Gastroenterol, 95, pp.1130~1138 (2000)
104. Angulo P, "Small-duct primary sclerosing cholangitis: a long-term follow-up study", Hepatology, 35, pp.1494~1500 (2002)
105. Chazouillères O, "Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy", Hepatology, 28, pp.296~301 (1998)
106. Czaja AJ, "Frequency and nature of the variant syndromes of autoimmune liver disease", Hepatology, 28, pp.360~365 (1998)
107. Czaja AJ, "The overlap syndromes of autoimmune hepatitis", Dig Dis Sci, 58, pp.326~343 (2013)
108. Kerkar N, "De-novo autoimmune hepatitis after liver transplantation", Lancet, 351, pp.409~413 (1998)
109. Heneghan MA, "Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults", Hepatology, 34, pp.464~470 (2001)
110. González-Koch A, "Recurrent autoimmune hepatitis after orthotopic liver transplantation", Liver Transpl, 7, pp.302~310 (2001)
111. Czaja AJ, "Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance", Liver Transpl, 8, pp.505~513 (2002)
112. Czaja AJ, "Recurrent autoimmune hepatitis after liver transplantation:a disease continuum or a fresh start?", Liver Transpl, 15, pp.1169~1171 (2009)
113. Czaja AJ, "Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation", Dig Dis Sci, 57, pp.2248~2266 (2012)
114. Neuberger J, "Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting", Transplantation, 37, pp.363~365 (1984)
115. Ratziu V, "Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease", J Hepatol, 30, pp.131~141 (1999)
116. Molmenti EP, "Incidence and recurrence of autoimmune", alloimmune hepatitis in liver transplant recipients, 2002, pp.8, 519~526
117. Duclos-Vallée JC, "A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence", Gut, 52, pp.893~897 (2003)
118. Vogel A, "Long-term outcome of liver transplantation for autoimmune hepatitis", Clin Transplant, 18, pp.62~69 (2004)
119. Prados E, "Outcome of autoimmune hepatitis after liver transplantation", Transplantation, 66, pp.1645~1650 (1998)
120. Hernandez HM, "Autoimmune hepatitis as a late complication of liver transplantation", J Pediatr Gastroenterol Nutr, 32, pp.131~136 (2001)
121. Montano-Loza AJ, "Risk factors for recurrence of autoimmune hepatitis after liver transplantation", Liver Transpl, 15, pp.1254~1261 (2009)
122. Campsen J, "Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal", Liver Transpl, 14, pp.1281~1286 (2008)
123. Gupta P, "De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation", Transplantation, 71, pp.664~668 (2001)
124. Aguilera I, "Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation", Clin Exp Immunol, 126, pp.535~539 (2001)
125. Cho JM, "De novo autoimmune hepatitis in Korean children after liver transplantation:a single institution’s experience", Transplant Proc, 43, pp.2394~2396 (2011)
126. Andries S, "Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine", Transplantation, 72, pp.267~272 (2001)
127. Duclos-Vallée JC, "Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation", Acta Gastroenterol Belg, 68, pp.331~336 (2005)
128. Aguilera I, "Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation", Liver Transpl, 10, pp.1166~1172 (2004)
129. Czaja AJ, "The variant forms of autoimmune hepatitis", Ann Intern Med, 125, pp.588~598 (1996)
130. Boberg KM, "Overlap syndromes:the International Autoimmune Hepatitis Group (IAIHG)position statement on a controversial issue", J Hepatol, 54, pp.374~385 (2011)
131. Chapman R, "Diagnosis and management of primary sclerosing cholangitis", Hepatology, 51, pp.660~678 (2010)
132. Lindor KD, "Primary biliary cirrhosis", Hepatology, 50, pp.291~308 (2009)
133. Papamichalis PA, "The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis", overlap syndromes and autoimmune hepatitis with concurrent other liver disorders, 2007, pp.4, 3~
134. Gatselis NK, "Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?", Dig Liver Dis, 42, pp.807~812 (2010)
135. Kuiper EM, "Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome", Clin Gastroenterol Hepatol, 8, pp.530~534 (2010)
136. Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
137. Björnsson E, "Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis", Clin Gastroenterol Hepatol, 9, pp.57~63 (2011)
138. Czaja AJ, "Review article: the management of autoimmune hepatitis beyond consensus guidelines", Aliment Pharmacol Ther, 38, pp.343~364 (2013)
139. Johnson PJ, "Meeting report: International Autoimmune Hepatitis Group", Hepatology, 18, pp.998~1005 (1993)
140. Czaja A, "Validation of scoring system for diagnosis of autoimmune hepatitis", Dig Dis Sci, 41, pp.305~314 (1996)
141. Yeoman AD, "Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease", Hepatology, 50, pp.538~545 (2009)
142. Boberg KM, "Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis", Hepatology, 23, pp.1369~1376 (1996)
143. Czaja AJ, "Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria", Gastroenterology, 140, pp.1472~1480 (2011)
144. Talwalkar JA, "Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system", Am J Gastroenterol, 97, pp.1191~1197 (2002)
145. Silveira MG, "Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes", Am J Gastroenterol, 102, pp.1244~1250 (2007)
146. Neuhauser M, "Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis", Am J Gastroenterol, 105, pp.345~353 (2010)
147. Fujiwara K, "Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis", Liver Int, 31, pp.1013~1020 (2011)
148. Homberg JC, "Chronic active hepatitis associated with antiliver", kidney microsome antibody type 1: a second type of “autoimmune” hepatitis, 1987, pp.7, 1333~1339
149. Czaja AJ, "Frequency and significance of antibodies to liver", kidney microsome type 1 in adults with chronic active hepatitis, 1992, pp.103, 1290~2095
150. Strettell MD, "Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis", Gastroenterology, 112, pp.2028~2035 (1997)
151. Czaja AJ, "Genetic distinctions between types 1 and 2 autoimmune hepatitis", Am J Gastroenterol, 92, pp.2197~2200 (1997)
152. Bittencourt PL, "Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2", Am J Gastroenterol, 94, pp.1906~1913 (1999)
153. Djilali-Saiah I, "HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis", J Hepatol, 45, pp.844~850 (2006)
154. Czaja AJ, "The validity and importance of subtypes in autoimmune hepatitis: a point of view", Am J Gastroenterol, 90, pp.1206~1211 (1995)
155. Muratori P, "Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype", Aliment Pharmacol Ther, 41, pp.1281~1287 (2015)
156. Czaja AJ, "Performance parameters of the conventional serological markers for autoimmune hepatitis", Dig Dis Sci, 56, pp.545~554 (2011)
157. Loria P, "Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates", Dig Dis Sci, 48, pp.2173~2181 (2003)
158. Adams LA, "The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 99, pp.1316~1320 (2004)
159. Couto CA, "Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis", Hepatology, 59, pp.592~600 (2014)
160. Czaja AJ, "Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis", Gastroenterology, 107, pp.200~207 (1994)
161. Czaja AJ, "Frequency and significance of antibodies to histones in autoimmune hepatitis", J Hepatol, 23, pp.32~38 (1995)
162. Czaja AJ, "Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis", Hepatology, 24, pp.1068~1073 (1996)
163. Gregorio GV, "Autoimmune hepatitis", sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study, 2001, pp.33, 544~553
164. Reddy KR, "Absence of anti-LKM-1antibody in hepatitis C viral infection in the United States of America", J Viral Hepat, 2, pp.175~179 (1995)
165. Abuaf N, "Non-organ specific autoantibodies associated with chronic C virus hepatitis", J Hepatol, 18, pp.359~364 (1993)
166. Muratori P, "Evidence of a genetic basis for the different geographic occurrences of liver", kidney microsomal antibody type 1 in hepatitis C, 2007, pp.52, 179~184
167. Manns MP, "LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase", J Clin Invest, 88, pp.1370~1378 (1991)
168. Ma Y, "Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule", J Immunol, 169, pp.277~285 (2002)
169. Czaja AJ, "Autoantibodies in autoimmune liver disease", Adv Clin Chem, 40, pp.127~164 (2005)
170. Czaja AJ, "The role of autoantibodies as diagnostic markers of autoimmune hepatitis", Expert Rev Clin Immunol, 2, pp.33~48 (2006)
171. Czaja AJ, "Autoantibodies in the diagnosis and management of liver disease", J Clin Gastroenterol, 37, pp.315~329 (2003)
172. Chretien-Leprince P, "Diagnostic value of anti-F-actin antibodies in a French multicenter study", Ann N Y Acad Sci, 1050, pp.266~273 (2005)
173. Frenzel C, "Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis", Am J Gastroenterol, 101, pp.2731~2736 (2006)
174. Granito A, "Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis", J Clin Pathol, 59, pp.280~284 (2006)
175. Martinez-Neira R, "An actin-myosin functional assay for analysis of smooth muscle (anti-microfilament)autoantibodies in human plasma", J Immunol Methods, 338, pp.63~66 (2008)
176. Soares A, "Smooth muscle autoantibodies with F-actin specificity", Autoimmun Rev, 8, pp.713~716 (2009)
177. Czaja AJ, "Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis", Gastroenterology, 139(e4), pp.58~72 (2010)
178. Chan Y, "Human skeletal musclespecific alpha-actinin-2 and -3 isoforms form homodimers and heterodimers in vitro and in vivo", Biochem Biophys Res Commun, 248, pp.134~139 (1998)
179. Efe C, "Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study", Liver Int, 33, pp.190~196 (2013)
180. Ballot E, "Antibodies to soluble liver antigen:an additional marker in type 1 auto-immune hepatitis", J Hepatol, 33, pp.208~215 (2000)
181. Czaja AJ, "Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis", Gastroenterology, 105, pp.1522~1528 (1993)
182. Wies I, "Identification of target antigen for SLA", LP autoantibodies in autoimmune hepatitis, 2000, pp.355, 1510~1515
183. Volkmann M, "SLA", LP, J Autoimmun, pp.2010, 34[DOI]
184. Schramm C, "Pregnancy in autoimmune hepatitis: outcome and risk factors", Am J Gastroenterol, 101, pp.556~560 (2006)
185. Liaskos C, "Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis (abstract)", J Hepatol, 46(1), pp.S250~ (2007)
186. Eyraud V, "Significance of antibodies to soluble liver antigen", liver pancreas: a large French study, 2009, pp.29, 857~864
187. Mulder AH, "Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases", Hepatology, 17, pp.411~417 (1993)
188. Bansi D, "Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass", J Hepatol, 24, pp.581~586 (1996)
189. Terjung B, "p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ", Gut, 59, pp.808~816 (2010)
190. Zauli D, "Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis", Hepatology, 25, pp.1105~1107 (1997)
191. Terjung B, "“Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines", Gastroenterology, 119, pp.310~322 (2000)
192. Sobajima J, "High mobility group (HMG)non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis", Gut, 44, pp.867~873 (1999)
193. Elkayam O, "Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena", Am J Med, 105, pp.484~487 (1998)
194. Terjung B, "Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”?", Clin Rev Allergy Immunol, 36, pp.40~51 (2009)
195. Zachou K, "Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease", J Autoimmune Dis, 1, pp.2~ (2004)
196. Roozendaal C, "Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases", J Hepatol, 32, pp.734~741 (2000)
197. Schwarze C, "IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis", Clin Exp Immunol, 133, pp.283~289 (2003)
198. McFarlane BM, "Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders", J Hepatol, 3, pp.196~205 (1986)
199. Treichel U, "Meyer zum Büschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis", Hepatology, 11, pp.606~612 (1990)
200. Treichel U, "Demographics of antiasialoglycoprotein receptor autoantibodies in autoimmune hepatitis", Gastroenterology, 107, pp.799~804 (1994)
201. Czaja AJ, "Frequency and significance of antibodies to asialoglycoprotein receptor in type 1autoimmune hepatitis", Dig Dis Sci, 41, pp.1733~1740 (1996)
202. Hajoui O, "Auto-antibodies to the asialoglycoprotein receptor in sera of children with auto-immune hepatitis", Eur J Pediatr, 159, pp.310~313 (2000)
203. Husa P, "Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients", Acta Virol, 45, pp.7~11 (2001)
204. Yoshioka M, "Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases", Acta Med Okayama, 56, pp.99~105 (2002)
205. Johnson PJ, "Autoimmune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies", J Gastroenterol Hepatol, 5, pp.244~251 (1990)
206. McFarlane IG, "Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis", Lancet, 2, pp.954~956 (1984)
207. Roggenbuck D, "Asialoglycoprotein receptor (ASGPR): a peculiar target of liverspecific autoimmunity", Auto Immun Highlights, 3, pp.119~125 (2012)
208. Muratori L, "Liver", kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis, 1998, pp.42, 721~726
209. Martini E, "Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2", Hepatology, 8, pp.1662~1666 (1988)
210. Abuaf N, "Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis", Hepatology, 16, pp.892~898 (1992)
211. Lenzi M, "Liver cytosolic 1 antigenantibody system in type 2 autoimmune hepatitis and hepatitis C virus infection", Gut, 36, pp.749~754 (1995)
212. Ballot E, "Detection on immunoblot of new proteins from the soluble fraction of the cell recognized either by anti-liver-kidney microsome antibodies type 1 or by anti-liver cytosol antibodies type 1: relationship with hepatitis C virus infection", Clin Immunol Immunopathol, 80(3 Pt 1), pp.245~254 (1996)
213. Béland K, "Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection", J Autoimmun, 22, pp.159~166 (2004)
214. Rigopoulou EI, "Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis", J Autoimmune Dis, 4, pp.2~ (2007)
215. Han S, "Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease", Hepatology, 21, pp.58~62 (1995)
216. Czaja AJ, "Nonstandard antibodies as prognostic markers in autoimmune hepatitis", Autoimmunity, 37, pp.195~201 (2004)
217. Muratori L, "Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques", J Immunol Methods, 187, pp.259~264 (1995)
218. Bridoux-Henno L, "Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody", Clin Gastroenterol Hepatol, 2, pp.825~830 (2004)
219. Lapierre P, "Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis", Gastroenterology, 116, pp.643~649 (1999)
220. Muratori L, "Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1", Hepatology, 34, pp.494~501 (2001)
221. Lapierre P, "Characterization of the B cell response of patients with anti-liver cytosol autoantibodies in type 2 autoimmune hepatitis", Eur J Immunol, 33, pp.1869~1878 (2003)
222. Renous R, "Characterization of the antigenicity of the formiminotransferasecyclodeaminase in type 2 autoimmune hepatitis", Exp Cell Res, 292, pp.332~341 (2004)
223. Summerskill WH, "Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared", Gut, 16, pp.876~883 (1975)
224. Sandborn WJ, "A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate", Am J Gastroenterol, 91, pp.423~433 (1996)
225. Allison AC, "Immunosuppressive drugs: the first 50 years and a glance forward", Immunopharmacology, 47, pp.63~83 (2000)
226. Rosenkrantz JG, "Azathioprine (Imuran) and pregnancy", Am J Obstet Gynecol, 97, pp.387~394 (1967)
227. de Boer NK, "Azathioprine use during pregnancy:unexpected intrauterine exposure to metabolites", Am J Gastroenterol, 101, pp.1390~1392 (2006)
228. Candia L, "Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma", Semin Arthritis Rheum, 35, pp.49~56 (2005)
229. Heneghan MA, "Management and outcome of pregnancy in autoimmune hepatitis", Gut, 48, pp.97~102 (2001)
230. Francella A, "The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study", Gastroenterology, 124, pp.9~17 (2003)
231. Werner M, "Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?", Scand J Gastroenterol, 42, pp.986~991 (2007)
232. Akbari M, "Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease", Inflamm Bowel Dis, 19, pp.15~22 (2013)
233. Casanova MJ, "Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease", Am J Gastroenterol, 108, pp.433~440 (2013)
234. Kanzler S, "Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience", Z Gastroenterol, 39, pp.339-341~344-338 (2001)
235. Kanzler S, "Duration of immunosuppressive therapy in autoimmune hepatitis", J Hepatol, 34, pp.354~355 (2001)
236. Sahasranaman S, "Clinical pharmacology and pharmacogenetics of thiopurines", Eur J Clin Pharmacol, 64, pp.753~767 (2008)
237. Ben Ari Z, "Azathioprineinduced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis", J Hepatol, 23, pp.351~354 (1995)
238. Langley PG, "Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis", J Hepatol, 37, pp.441~447 (2002)
239. Heneghan MA, "Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis", J Hepatol, 45, pp.584~591 (2006)
240. Czaja AJ, "Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis", Dig Dis Sci, 51, pp.968~975 (2006)
241. Montano-Loza AJ, "Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse", Am J Gastroenterol, 102, pp.1005~1012 (2007)
242. Czaja AJ, "Rapidity of treatment response and outcome in type 1autoimmune hepatitis", J Hepatol, 51, pp.161~167 (2009)
243. Czaja AJ, "Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features", Gastroenterology, 80, pp.687~692 (1981)
244. Czaja AJ, "Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis", Aliment Pharmacol Ther, 39, pp.1043~1058 (2014)
245. Czaja AJ, "Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis", Hepatology, 4, pp.622~627 (1984)
246. Czaja AJ, "Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis", Hepatology, 35, pp.890~897 (2002)
247. van Gerven NM, "Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission", J Hepatol, 58, pp.141~147 (2013)
248. Czaja AJ, "Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis", Gastroenterology, 92, pp.215~219 (1987)
249. Czaja AJ, "Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission", Gastroenterology, 78, pp.518~523 (1980)
250. Hegarty JE, "Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis", Hepatology, 3, pp.685~689 (1983)
251. Montano-Loza AJ, "Consequences of treatment withdrawal in type 1 autoimmune hepatitis", Liver Int, 27, pp.507~515 (2007)
252. Montano-Loza AJ, "Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease", Hepatology, 46, pp.1138~1145 (2007)
253. Selvarajah V, "Systematic review:managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs", Aliment Pharmacol Ther, 36, pp.691~707 (2012)
254. Czaja AJ, "Safety issues in the management of autoimmune hepatitis", Expert Opin Drug Saf, 7, pp.319~333 (2008)
255. Bajaj JS, "Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared to autoimmune hepatitis: a tertiary referral center experience", Am J Gastroenterol, 100, pp.1121~1125 (2005)
256. Czaja AJ, "Management of recalcitrant autoimmune hepatitis", Curr Hepatitis Rep, 12, pp.66~77 (2013)
257. Schalm SW, "Failure of customary treatment in chronic active liver disease: causes and management", Ann Clin Res, 8, pp.221~227 (1976)
258. Seela S, "Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy", Liver Int, 25, pp.734~739 (2005)
259. Czaja AJ, "Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis", Hepatology, 11, pp.1044~1049 (1990)
260. Allison AC, "Mycophenolate mofetil and its mechanisms of action", Immunopharmacology, 47, pp.85~118 (2000)
261. Allison AC, "Mechanisms of action of mycophenolate mofetil", Lupus, 14(1), pp.S2~S8 (2005)
262. Perez-Aytes A, "In utero exposure to mycophenolate mofetil: a characteristic phenotype?", Am J Med Genet A, 146, pp.1~7 (2008)
263. Anderka MT, "Reviewing the evidence for mycophenolate mofetil as a new teratogen:case report and review of the literature", Am J Med Genet A, 149, pp.1241~1248 (2009)
264. Klieger-Grossmann C, "Prenatal exposure to mycophenolate mofetil: an updated estimate", J Obstet Gynaecol Can, 32, pp.794~797 (2010)
265. Lin AE, "An additional patient with mycophenolate mofetil embryopathy:cardiac and facial analyses", Am J Med Genet A, 155, pp.748~756 (2011)
266. Woynarowski M, "Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents", J Pediatr, 163(e1), pp.1347~1353 (2013)
267. Mieli-Vergani G, "Budesonide for juvenile autoimmune hepatitis? Not yet", J Pediatr, 163, pp.1246~1248 (2013)
268. Geier A, "Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC", World J Gastroenterol, 9, pp.2681~2685 (2003)
269. Efe C, "Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome", Autoimmun Rev, 11, pp.330~334 (2012)
270. Lohse AW, "Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment", J Hepatol, 54, pp.837~839 (2011)
271. Czaja AJ, "Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis", Gastroenterology, 119, pp.1312~1316 (2000)
272. Czaja AJ, "Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree", J Hepatol, 51, pp.8~10 (2009)
273. Seikaly MG, "Mycophenolate mofetil: is it worth the cost? The infavor opinion", Pediatr Transplant, 3, pp.79~82 (1999)
274. Alvarez F, "Short-term cyclosporine induces a remission of autoimmune hepatitis in children", J Hepatol, 30, pp.222~227 (1999)
275. Cuarterolo M, "Follow-up of children with autoimmune hepatitis treated with cyclosporine", J Pediatr Gastroenterol Nutr, 43, pp.635~639 (2006)
276. Larsen FS, "Lowdose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis", World J Gastroenterol, 13, pp.3232~3236 (2007)
277. Hess AD, "Cyclosporineinduced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression", Transplant Proc, 25, pp.2811~2813 (1993)
278. Lohse AW, "De novo autoimmune hepatitis after liver transplantation", Hepatol Res, 37(3), pp.S462~ (2007)
279. Chatur N, "Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus", Liver Int, 25, pp.723~727 (2005)
280. Kerkar N, "Rapamycin successfully treats post-transplant autoimmune hepatitis", Am J Transplant, 5, pp.1085~1089 (2005)
281. Santos ES, "Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature", Liver Int, 26, pp.625~629 (2006)
282. Evans JT, "Rituximabresponsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis", J Clin Gastroenterol, 42, pp.862~863 (2008)
283. Barth E, "A case of autoimmune hepatitis treated with rituximab", Case Rep Gastroenterol, 4, pp.502~509 (2010)
284. Carey EJ, "Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome", Rev Med Chil, 139, pp.1484~1487 (2011)
285. Burak KW, "Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy", Can J Gastroenterol, 27, pp.273~280 (2013)
286. Germano V, "Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis", Ann Rheum Dis, 64, pp.1519~1520 (2005)
287. Marques M, "Infliximab-induced lupuslike syndrome associated with autoimmune hepatitis", Inflamm Bowel Dis, 14, pp.723~725 (2008)
288. Fairhurst DA, "Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis", Clin Exp Dermatol, 34, pp.421~422 (2009)
289. Ghabril M, "Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases", Clin Gastroenterol Hepatol, 11(e3), pp.558~564 (2013)
290. Dulai PS, "Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review", Clin Gastroenterol Hepatol, 12, pp.1443~1451 (2014)
291. Björnsson ES, "Risk of druginduced liver injury from tumor necrosis factor antagonists", Clin Gastroenterol Hepatol, 13, pp.602~608 (2015)
292. Núñez-Martínez O, "Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation", Transplant Proc, 35, pp.1857~1858 (2003)
293. Tripathi D, "Autoimmune hepatitis and liver transplantation:indications, results, and management of recurrent disease", Semin Liver Dis, 29, pp.286~296 (2009)
294. Neuberger J, "Transplantation for autoimmune hepatitis", Semin Liver Dis, 22, pp.379~386 (2002)
295. Martin SR, "Outcomes in children who underwent transplantation for autoimmune hepatitis", Liver Transpl, 17, pp.393~401 (2011)
296. Birnbaum AH, "Recurrence of autoimmune hepatitis in children after liver transplantation", J Pediatr Gastroenterol Nutr, 25, pp.20~25 (1997)
297. Milkiewicz P, "Recurrence of autoimmune hepatitis after liver transplantation", Transplantation, 68, pp.253~256 (1999)
298. Reich DJ, "Liver transplantation for autoimmune hepatitis", Hepatology, 32(4 Pt 1), pp.693~700 (2000)
299. Yusoff IF, "Disease recurrence after liver transplantation in Western Australia", J Gastroenterol Hepatol, 17, pp.203~207 (2002)
300. Czaja AJ, "Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part II", Inflamm Allergy Drug Targets, 11, pp.351~363 (2012)
301. Chen M, "Adoptive transfer of human gingivaderived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation", Arthritis Rheum, 65, pp.1181~1193 (2013)
302. Scalapino KJ, "CTLA-4: a key regulatory point in the control of autoimmune disease", Immunol Rev, 223, pp.143~155 (2008)
303. Dhirapong A, "Therapeutic effect of cytotoxic T lymphocyte antigen 4", immunoglobulin on a murine model of primary biliary cirrhosis, 2013, pp.57, 708~715
304. Smith CA, "Antibodies to CD3", T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures, 1989, pp.337, 181~184
305. Perruche S, "CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells", Nat Med, 14, pp.528~535 (2008)
306. Ochi H, "New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity", J Neurol Sci, 274, pp.9~12 (2008)
307. Chatenoud L, "Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice", Proc Natl Acad Sci U S A, 91, pp.123~127 (1994)
308. Herold KC, "Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus", N Engl J Med, 346, pp.1692~1698 (2002)
309. Longhi MS, "Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease", J Hepatol, 41, pp.31~37 (2004)
310. Longhi MS, "Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis", J Immunol, 176, pp.4484~4491 (2006)
311. Peiseler M, "FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency", J Hepatol, 57, pp.125~132 (2012)
312. Kido M, "Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling", Gastroenterology, 135, pp.1333~1343 (2008)
313. Tanaka H, "Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells", Clin Exp Immunol, 178, pp.253~261 (2014)
314. Novak J, "Mechanism of regulation of autoimmunity by iNKT cells", Cytokine, 53, pp.263~270 (2011)
315. Van Kaer L, "Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens", Immunotherapy, 3, pp.59~75 (2011)
316. Dennert G, "The role of NKT cells in animal models of autoimmune hepatitis", Crit Rev Immunol, 26, pp.453~473 (2006)
317. Kawamura H, "P2X7 receptors regulate NKT cells in autoimmune hepatitis", J Immunol, 176, pp.2152~2160 (2006)
318. Francois S, "Human mesenchymal stem cells provide protection against radiation-induced liver injury by antioxidative process, vasculature protection, hepatocyte differentiation, and trophic effects", Biomed Res Int, 2013, pp.151679~ (2013)
319. Ringdén O, "Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease", Transplantation, 81, pp.1390~1397 (2006)
320. Voswinkel J, "Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review", Clin Rev Allergy Immunol, 45, pp.180~192 (2013)
321. Peng Y, "Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study", Transplantation, 95, pp.161~168 (2013)
322. Czaja AJ, "Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis", Aliment Pharmacol Ther, 39, pp.385~406 (2014)
323. Czaja AJ, "Hepatic inflammation and progressive liver fibrosis in chronic liver disease", World J Gastroenterol, 20, pp.2515~2532 (2014)
324. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
325. Harrison SA, "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.2485~2490 (2003)
326. Mato JM, "S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebocontrolled, double-blind, multicenter clinical trial", J Hepatol, 30, pp.1081~1089 (1999)
327. Feld JJ, "S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders", Gastroenterology, 140, pp.830~839 (2011)
328. Colmenero J, "Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C", Am J Physiol Gastrointest Liver Physiol, 297, pp.G726~G734 (2009)
329. Sanz-Cameno P, "Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis", J Hepatol, 37, pp.723~729 (2002)
330. Pemberton PW, "Oxidant stress in type I autoimmune hepatitis:the link between necroinflammation and fibrogenesis?", Biochim Biophys Acta, 1689, pp.182~189 (2004)
331. Singal AK, "Antioxidants as therapeutic agents for liver disease", Liver Int, 31, pp.1432~1448 (2011)
332. Moreno-Otero R, "May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients?", Dig Dis Sci, 58, pp.1440~1441 (2013)
333. Ueno Y, "Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model", J Pharmacol Sci, 105, pp.201~205 (2007)
334. Canbay A, "The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse", J Pharmacol Exp Ther, 308, pp.1191~1196 (2004)
335. Anstee QM, "Impact of pan-caspase inhibition in animal models of established steatosis and nonalcoholic steatohepatitis", J Hepatol, 53, pp.542~550 (2010)
336. Yoshida N, "Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis by caspase inhibitor", J Gastroenterol Hepatol, 22, pp.2015~2021 (2007)
337. Pockros PJ, "Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C", Hepatology, 46, pp.324~329 (2007)
338. Arends JE, "Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells", Apoptosis, 16, pp.959~966 (2011)
339. Faubel S, "Caspases as drug targets in ischemic organ injury", Curr Drug Targets Immune Endocr Metabol Disord, 5, pp.269~287 (2005)
340. Petta S, "Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferonbased therapy in genotype 1 chronic hepatitis C", Hepatology, 51, pp.1158~1167 (2010)
341. Farnik H, "Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients", Hepatology, 58, pp.1270~1276 (2013)
342. Trépo E, "Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease", J Hepatol, 59, pp.344~350 (2013)
343. Efe C, "Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis", Dig Dis Sci, 59, pp.3035~3042 (2014)
344. Beyazit Y, "Oxidative stress might play a role in low serum vitamin D associated liver fibrosis among patients with autoimmune hepatitis", Dig Dis Sci, 60, pp.1106~1108 (2015)
345. Dasarathy J, "Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease", Liver Int, 34, pp.e118~e127 (2014)
346. Arnson Y, "Vitamin D and autoimmunity:new aetiological and therapeutic considerations", Ann Rheum Dis, 66, pp.1137~1142 (2007)
347. Codoñer-Franch P, "Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children", J Pediatr, 161, pp.848~854 (2012)
348. Smyk DS, "Vitamin D in autoimmune liver disease", Clin Res Hepatol Gastroenterol, 37, pp.535~545 (2013)
349. Czaja AJ, "Transitioning from idiopathic to explainable autoimmune hepatitis", Dig Dis Sci, 60, pp.2881~2900 (2015)

관련 논문AI추천